ArticleTechnical innovations & patient support in radiation oncology2026
Reirradiation of lower gastrointestinal Cancer: A survey of ongoing trials by the Reirradiation Collaborative group (ReCOG).
Article in Technical innovations & patient support in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Pelvic reirradiation is increasingly used for locally recurrent rectal and anal cancers, either to facilitate salvage surgery or to improve local control when surgery is not feasible. However, prospective evidence remains limited, and studies often lack sufficient methodological detail to support interpretation across trials. We aimed to identify ongoing lower gastrointestinal reirradiation trials and describe characteristics, heterogeneity, and evidence gaps. Materials and methods: The Reirradiation Collaborative Group lower gastrointestinal working group performed a registry-based search for prospective pelvic reirradiation studies in rectal and anal cancer. Eligible studies were prospective, observational or interventional trials involving reirradiation for lower gastrointestinal cancers. Principal investigators were invited to complete a structured 40-item questionnaire covering trial design, reirradiation definition, clinical intent, endpoints, use of patient-reported outcomes (PROs), radiotherapy technique, target, and cumulative dose evaluation. Results: Of 27 identified studies, 21 were eligible and investigators from 9 trials completed the questionnaire. Most trials used type 1 reirradiation (overlap of irradiated volumes) according to the ESTRO/EORTC framework, but substantial heterogeneity was observed in dose-fractionation, modality, target volume margins, organs of interest, dose objectives, and cumulative dose methodology. Toxicity was assessed with CTCAE, and most studies incorporated PROs, although instruments and timepoints varied. Based on these findings, we propose 12 pragmatic recommendations for lower gastrointestinal reirradiation trials. Conclusion: Prospective lower gastrointestinal reirradiation trials show methodological heterogeneity. Standardization of definitions, dosimetric data capture, and toxicity and PRO reporting may improve interpretability, comparability, and future evidence synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.